Cyclooxygenase-2 inhibition for the prophylaxis and treatment of preinvasive breast cancer in a Her-2/Neu mouse model

Cancer Prevention Research

Volumn 3, Issue 2, 2010, Pages 202-211

  Tran Thanh, Danh ^a,b   Buttars, Stephen ^a,c   Wen, Yanxia ^a   Wilson, Christine ^d   Done, Susan J ^a,b,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 9; CELECOXIB; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROSTAGLANDIN; PROSTAGLANDIN E2; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER INCIDENCE; CANCER MODEL; CANCER PREVENTION; CANCER THERAPY; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; INTRADUCTAL CARCINOMA; LUNG METASTASIS; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENE; TRANSGENIC MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CYCLOOXYGENASE 2; DINOPROSTONE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENZYME INHIBITORS; FEMALE; GENES, ERBB-2; IMMUNOHISTOCHEMISTRY; MICE; MICE, TRANSGENIC; PYRAZOLES; SULFONAMIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77949752006     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0181     Document Type: Article

References (52)

1. Hofvind S, Sorum R, Thoresen S. Incidence and tumor characteristics of breast cancer diagnosed before and after implementation of a population-based screening-program. Acta Oncol 2008;47:225-31.
2. Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med 2004;350:1430-41.
3. Cornfield DB, Palazzo JP, Schwartz GF, et al. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone. Cancer 2004;100:2317-27.
4. Perrone G, Santini D, Vincenzi B, et al. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features. Histopathology 2005;46:561-8.
5. Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 2002;62:1676-81.
6. Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000;89:2637-45.
7. ShimV, GauthierML, Sudilovsky D, et al. Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium. Cancer Res 2003;63:2347-50.
8. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632-5.
9. Davies G, Salter J, Hills M, Martin LA, Sacks N, Dowsett M. Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin Cancer Res 2003;9:2651-6.
10. Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJ. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 2004;90:423-9.
11. Spizzo G, Gastl G, Wolf D, et al. Correlation of COX-2 and ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br J Cancer 2003;88:574-8.
12. Sheng H, Shao J, Washington MK, DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001;276:18075-81.
13. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16.
14. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 1997;94:3336-40.
15. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998;58:362-6.
16. Liu CH, Chang SH, Narko K, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001;276:18563-9.
17. Phillips RK, Wallace MH, Lynch PM, et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002;50:857-60.
18. Khuder SA, Mutgi AB. Breast cancer and NSAID use: a metaanalysis. Br J Cancer 2001;84:1188-92.
19. Connolly EM, Harmey JH, O'Grady T, et al. Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer. Br J Cancer 2002;87:231-7.
20. Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000;60:2101-3.
21. Howe LR, Subbaramaiah K, Patel J, et al. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res 2002;62:5405-7.
22. Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ, Mukherjee P. Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res 2004;2:632-42.
23. Barnes NL, Warnberg F, Farnie G, et al. Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer. Br J Cancer 2007;96:575-82.
24. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 1992;89:10578-82.
25. Cardiff RD, Wellings SR. The comparative pathology of human and mouse mammary glands. J Mammary Gland Biol Neoplasia 1999;4:105-22.
26. Lanza-Jacoby S, Miller S, Flynn J, et al. The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in her-2/neu mice. Cancer Epidemiol Biomarkers Prev 2003;12:1486-91.
27. Abou-Issa HM, Alshafie GA, Seibert K, Koki AT, Masferrer JL, Harris RE. Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis. Anticancer Res 2001;21:3425-32.
28. Mukherjee P, Madsen CS, Ginardi AR, et al. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer. J Immunother 2003;26:47-62.
29. Ellis IO, Bartlett J, Dowsett M, et al. Best practice no 176: updated recommendations for HER2 testing in the UK. J Clin Pathol 2004;57:233-7.
30. Tan PH, Bay BH, Yip G, et al. Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Mod Pathol 2005;18:374-81.
31. Pradelles P, Grassi J, Maclouf J. Enzyme immunoassays of eicosanoids using acetylcholine esterase as label: An alternative to radio-immunoassay. Anal Chem 1985;57:1170-3.
32. Hahn T, Alvarez I, Kobie JJ, et al. Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer. Int J Cancer 2006;118:2220-31.
33. Blewett AJ, Varma D, Gilles T, Libonati JR, Jansen SA. Development and validation of a high-performance liquid chromatography-electrospray mass spectrometry method for the simultaneous determination of 23 eicosanoids. J Pharm Biomed Anal 2008;46:653-62.
34. Lerwill MF. Current practical applications of diagnostic immunohistochemistry in breast pathology. Am J Surg Pathol 2004;28:1076-91.
35. Bundred NJ, Barnes NL. Potential use of COX-2-aromatase inhibitor combinations in breast cancer. Br J Cancer 2005;93 Suppl 1:S10-5.
36. Frech MS, Halama ED, Tilli MT, et al. Deregulated estrogen receptor α expression in mammary epithelial cells of transgenic mice results in the development of ductal carcinoma in situ. Cancer Res 2005;65:681-5.
37. Namba R, Maglione JE, Young LJ, et al. Molecular characterization of the transition to malignancy in a genetically engineered mouse-based model of ductal carcinoma in situ. Mol Cancer Res 2004;2:453-63.
38. Schulze-Garg C, Lohler J, Gocht A, Deppert W. A transgenic mouse model for the ductal carcinoma in situ (DCIS) of the mammary gland. Oncogene 2000;19:1028-37.
39. Miller FR, Santner SJ, Tait L, Dawson PJ. MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst 2000;92:1185-6.
40. Richert MM, Schwertfeger KL, Ryder JW, Anderson SM. An atlas of mouse mammary gland development. J Mammary Gland Biol Neoplasia 2000;5:227-41.
41. Badawi AF, Archer MC. Effect of hormonal status on the expression of the cyclooxygenase 1 and 2 genes and prostaglandin synthesis in rat mammary glands. Prostaglandins Other Lipid Mediat 1998;56:167-81.
42. Chandrasekharan S, Foley NA, Jania L, Clark P, Audoly LP, Koller BH. Coupling of COX-1 to mPGES1 for prostaglandin E2 biosynthesis in the murine mammary gland. J Lipid Res 2005;46:2636-48.
43. Morham SG, Langenbach R, Loftin CD, et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995;83:473-82.
44. Howe LR, Chang SH, Tolle KC, et al. HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res 2005;65:10113-9.
45. Tanaka T, Haneda S, Imakawa K, Sakai S, Nagaoka K. A microRNA, miR-101a, controls mammary gland development by regulating cyclooxygenase-2 expression. Differentiation 2009;77:181-7.
46. Brown PH, Subbaramaiah K, Salmon AP, et al. Combination chemo-prevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid. Cancer Prev Res 2008;1:208-14.
47. Hu M, Peluffo G, Chen H, Gelman R, Schnitt S, Polyak K. Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc Natl Acad Sci U S A 2009;106:3372-7.
48. Paulson SK, Kaprak TA, Gresk CJ, et al. Plasma protein binding of celecoxib in mice, rat, rabbit, dog and human. Biopharm Drug Dispos 1999;20:293-9.
49. Solomon SD, Wittes J, Finn PV, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: The cross trial safety analysis. Circulation 2008;117:2104-13.
50. Harris RE, Chlebowski RT, Jackson RD, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the women's health initiative. Cancer Res 2003;63:6096-101.
51. Marshall SF, Bernstein L, Anton-Culver H, et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst 2005;97:805-12.
52. Zhao X, Goswami M, Pokhriyal N, et al. Cyclooxygenase-2 expression during immortalization and breast cancer progression. Cancer Res 2008;68:467-75.